medigraphic.com

2015, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (2)

Safety Nonsteroidal antiinflammatory drugs

Oscanoa-Espinozaa TJ

Language: Spanish
References: 36
Page: 172-179
PDF size: 223.82 Kb.


ABSTRACT

The choice of a specific medication belonging to a drug class is under the criteria of efficacy, safety, cost and suitability. NSAIDs currently constitute one of the most consumed drug in the world, so it is very important review of the safety aspects of this drug class. This review has the objective of analyze the safety of NSAIDs on 3 main criteria: gastrolesivity, cardiotoxicity and nephrotoxicity.


REFERENCES

  1. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348(10):883-890.

  2. Zhang Y, Coogan PF, Palmer JR, et al. Use of nonsteroidal anti-infl ammatory drugs and risk of breast cancer: the case-control surveillance study revisited. Am J Epidemiol. 2005;162(2):165-170.

  3. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-infl ammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327(7407):128-131.

  4. Dyer C. Benoxaprofen case makes legal history. Br Med J (Clin Res Ed). 1987;295(6589):39-40.

  5. Batlouni M. [Nonsteroidal anti-infl ammatory drugs: cardiovascular, cerebrovascular and renal effects]. Arq Bras Cardiol. 2010;94(4):556-63.

  6. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-infl ammatory drugs. J Biol Chem. 1993;25; 268(9):6610-4. Tolmetin 0.77 1.03 1.4 1.47 1.55 1.63 1.75 1.95 2.4 Diclofenaco Ketoprofeno Naproxeno Sulindac Ibuprofeno Fenoprofen Piroxicam Indometacina 0 0.5 1 1.5 Riesgo relativo 2 2.5 179 Oscanoa-Espinoza TJ Seguridad de los antiinfl amatorios no esteroideos Rev Med Inst Mex Seguro Soc. 2015;53(2):172-9

  7. Rao P, Knaus EE. Evolution of nonsteroidal anti-infl ammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;20; 11(2):81s-110s.

  8. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-infl ammatory drugs. Am J Med. 1998;104(3A):2S-8S; discussion 21S-22S.

  9. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 Aug 22-29;286(8):954-9.

  10. Mitchell JA, Evans TW. Cyclooxygenase-2 as a therapeutic target. Infl amm Res. 1998;47 Suppl 2:S88-92.

  11. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediator 2007; 82(1-4):85-94.

  12. Wallace JL, Devchand PR. Emerging roles for cyclooxygenase- 2 in gastrointestinal mucosal defense. Br J Pharmacol. 2005;145(3):275-82.

  13. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et.al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced infl ammation and indomethacininduced gastric úlceration. Cell. 1995;83(3):483-92.

  14. Tanaka A, Hase S, Miyazawa T, Takeuchi K. Upregulation of cyclooxygenase-2 by inhibition of cyclooxygenase- 1: a key to nonsteroidal anti-infl ammatory drug-induced intestinal damage. J Pharmacol Exp Ther. 2002;300(3):754-61.

  15. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119(3):706-14.

  16. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology. 1979;77(3):433-43.

  17. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specifi c inhibition of cyclo-oxygenase- 1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol. 2001;132(7):1565-73.

  18. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol. 1999;128(8):1659-66.

  19. Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology. 2000;119(2):512-20.

  20. Ehrlich K, Sicking C, Respondek M, Peskar BM. Interaction of cyclooxygenase isoenzymes, nitric oxide, and afferent neurons in gastric mucosal defense in rats. J Pharmacol Exp Ther. 2004;308(1):277-83. Epub 2003 Oct 20.

  21. Perini RF, Ma L, Wallace JL. Mucosal repair and COX- 2 inhibition. Curr Pharm Des. 2003;9(27):2207-11.

  22. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A. 2002; 99(20):13243-7. Epub 2002 Sep 13.

  23. Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, infl amed, and uúlcerated human gastric mucosa. Gut 2000;47(6):762-70.

  24. Tanaka A, Hatazawa R, Takahira Y, Izumi N, Filaretova L, Takeuchi K. Preconditioning stress prevents cold restraint stress-induced gastric lesions in rats: roles of COX-1, COX-2, and PLA2. Dig Dis Sci 2007; 52(2):478-87.

  25. Coruzzi G, Venturi N, Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinfl ammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed. 2007 Aug;78(2):96-110.

  26. Henry D, McGettigan P. Selective COX-2 inhibitors: a promise unfulfi lled? Gastroenterology 2007;132(2):790-4.

  27. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinfl ammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601.

  28. European Medicines Agency. European Medicines Agency recommends restricted use for piroxicam. Doc. Ref. EMEA/265144/2007. 25 June 2007 (ingresado el 17 de Julio 2011). Disponible en http:// www.ema.europa.eu/docs/en_GB/document_library/ Press_release/2009/11/WC500012655.pdf

  29. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et.al. Cardiovascular safety of non-steroidal anti-infl ammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.

  30. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368(9549):1771-81.

  31. McGettigan P, Henry D, Cardiovascular risk with nonsteroidal anti-infl ammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011 8(9): e1001098. doi:10.1371/journal. pmed.1001098

  32. McGettigan P, Henry D (2013) Use of non-steroidal anti- infl ammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-middle and high-income countries. PLoS Med 10(2): e1001388. doi:10.1371/journal.pmed.1001388

  33. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32. Epub 2006 Sep 12.

  34. Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-infl ammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9.

  35. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinfl ammatory drugs with acute renalfailure: A population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881-9. Epub 2006 Sep 27.

  36. Griffi n MR, Yared A, Ray WA. Nonsteroidal antiinfl ammatory drugs and acute renal failure in elderly persons. Am. J. Epidemiol. 2000,151(5)488-496.




2020     |     www.medigraphic.com